Developing a target treatment for multiple myeloma
Oncopeptides lead compound, named melflufen, is a peptidase potentiated therapy within oncology. Melflufen is a very potent anti-angiogenetic compound, triggers rapid, robust, and irreversible DNA damage and exerts it cytotoxicity through alkylation of DNA. Melflufen is currently undergoing Phase 2 efficacy studies in patients with relapsed and relapsed-refractory multiple myeloma. The peptidase targeting causes melflufen and its metabolites to accumulate in the diseased cells. This results in targeted delivery of the active moieties to the cancer cells, and thereby better treatment of the disease. news

Subscribe to our updates to stay informed

2015.06.12 NEW:Results Presented at EHA Show Significant Clinical Benefit for Patients Treated with Melflufen and Dexamethasone
June 11-14 DOWNLOAD

2015.06.04 Oncopeptides to Present Promising Phase I/II Data at EHA in Vienna
June 11-14 DOWNLOAD

2015.03.23 Oncopeptides Receives EMA and FDA Orphan Drug Designation for Melflufen in the Treatment of Multiple Myeloma DOWNLOAD

2014.12.05 Oncopeptides Presents Encouraging Preliminary Phase I/ II Clinical Data at ASH DOWNLOAD

2013.08.20 Oncopeptides Initiates Phase II Clinical Study with Melflufen in the Treatment of Multiple Myeloma Patients

Dana-Farber Cancer Institute, MA, USA is the lead investigator of a Phase 2 multi-centre clinical trial in multiple myeloma. This is being conducted in both the US and Western Europe.

If you are interested in finding out more about this trial please email:
After demonstrating proof of efficacy in man, Oncopeptides intends to take melflufen to market through a corporate parnership.

If you would like to discuss business opportunities with Oncopeptides contact our CEO, Jakob Lindberg or our Head of Business Development, Björn Hammarberg.